Intuitive Surgical, Inc. (NASDAQ:ISRG – Get Free Report) Director Amy L. Ladd sold 450 shares of the business’s stock in a transaction that occurred on Friday, September 13th. The shares were sold at an average price of $490.28, for a total transaction of $220,626.00. Following the completion of the sale, the director now directly owns 821 shares in the company, valued at approximately $402,519.88. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Intuitive Surgical Stock Up 0.3 %
NASDAQ:ISRG opened at $491.39 on Tuesday. The company’s 50 day moving average price is $464.67 and its 200-day moving average price is $422.79. Intuitive Surgical, Inc. has a 52 week low of $254.85 and a 52 week high of $496.18. The stock has a market cap of $174.30 billion, a price-to-earnings ratio of 88.70, a PEG ratio of 5.41 and a beta of 1.39.
Intuitive Surgical (NASDAQ:ISRG – Get Free Report) last posted its quarterly earnings results on Thursday, July 18th. The medical equipment provider reported $1.78 EPS for the quarter, beating analysts’ consensus estimates of $1.54 by $0.24. Intuitive Surgical had a net margin of 27.65% and a return on equity of 13.04%. The firm had revenue of $2.01 billion for the quarter, compared to analysts’ expectations of $1.97 billion. During the same quarter in the prior year, the company posted $1.18 earnings per share. The business’s revenue for the quarter was up 14.5% on a year-over-year basis. As a group, sell-side analysts anticipate that Intuitive Surgical, Inc. will post 5.22 earnings per share for the current year.
Institutional Investors Weigh In On Intuitive Surgical
Analysts Set New Price Targets
ISRG has been the topic of a number of analyst reports. Truist Financial upped their target price on shares of Intuitive Surgical from $450.00 to $515.00 and gave the stock a “buy” rating in a report on Tuesday, July 16th. Morgan Stanley increased their price target on shares of Intuitive Surgical from $375.00 to $460.00 and gave the stock an “equal weight” rating in a research note on Monday, July 15th. The Goldman Sachs Group started coverage on shares of Intuitive Surgical in a report on Thursday, May 30th. They issued a “buy” rating and a $500.00 price objective on the stock. Robert W. Baird upped their price objective on shares of Intuitive Surgical from $487.00 to $503.00 and gave the stock an “outperform” rating in a report on Friday, July 19th. Finally, Stifel Nicolaus upped their price objective on shares of Intuitive Surgical from $430.00 to $475.00 and gave the stock a “buy” rating in a report on Friday, July 19th. Six investment analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $446.45.
View Our Latest Stock Report on ISRG
Intuitive Surgical Company Profile
Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.
Read More
- Five stocks we like better than Intuitive Surgical
- 3 Grocery Stocks That Are Proving They Are Still Essential
- Palo Alto Analysts Drive it to New Highs: 50% Upside Is Possible
- How to Invest in the FAANG Stocks
- Roblox’s Growth Beyond Kids: Stock Set for Major Moves
- Why Special Dividends Can be a Delightful Surprise for Income Investors
- 5 Oversold Stocks to Buy Right Now
Receive News & Ratings for Intuitive Surgical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intuitive Surgical and related companies with MarketBeat.com's FREE daily email newsletter.